NCT04987294 - Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 2, 2022

Primary Completion Date

September 2, 2022

Study Completion Date

September 2, 2022

Conditions

HyperuricemiaGoutChronic Kidney Diseases

Interventions

DRUG

ALLN-346

ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration

DRUG

Placebo

Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules

Trial Locations (17)

11215

NY Total Medical Care, PC, Brooklyn

18017

Northeast Clinical Research Center, LLC, Bethlehem

20902

The Center of Rheumatology and Bone Research, Wheaton

28655

Burke Primary Care, Morganton

33013

Eastern Research, Inc., Hialeah

33016

Best Quality Research, Inc., Hialeah

New Generation of Medical Research, Hialeah

33185

Kendall South Medical Center, Inc., Miami

35294

University of Alabama at Birmingham, Birmingham

35660

Syed Research Consultants, LLC, Sheffield

35661

Syed Research Consultants, LLC, Muscle Shoals

39202

Elite Clinical Research, LLC, Jackson

44224

Summit research Group, LLC, Stow

75904

P&I Clinical Research, LLC, Lufkin

78224

Briggs Clinical Research, LLC, San Antonio

92691

Allameh Medical Corporation, Mission Viejo

99508

Orthopedic Physicians Alaska, Anchorage